References
- Carlson L A, Erikson I. Femoral-artery infusion of prostaglandin E, in severe peripheral vascular disease. Lancet 1973; i: 155–6
- Olsson A G, Nielsson E. The effect of intravenous prostacyclin on resting pains and healing of ischaemic ulcers in peripheral arterial disease. Prostaglandines Med 1981; 6: 329–39
- Belch J FF, McArdle B, Pollock J., et al. Epopros-tenol (prostacyclin) and severe arterial disease. A double blind trial. Lancet 1983; i: 315–7
- Tyler H M, Saxton CAPD, Parry M J. Administration to man of UK 37, 24801, a selective inhibitor of tromboxane synthetase. Lancet 1981; i: 629–32
- Jelnes R, Bülow J. Evaluation of a method of determination of the subcutaneous blood flow in the forefoot continuously over 24 hours. Scand J Clin Lab Invest 1984; 44: 85–90
- Jelnes R, Bülow J, Tønnesen K H. Subcutaneous adipose tissue blood flow in the forefoot during 24 hours. Labelling pattern and reproducibility. Scand J Clin Lab Invest 1987; 47: 223–7
- Jelnes R, Rasmussen L B, Eickhoff J H. Direct determination of the tissue-to-blood partition coefficient for xenon in human adipose tissue. Scand J Clin Lab Invest 1984; 44: 643–7
- Randall M J, Parry M J, Hawkeswood E, et al. UK-37248, a novel, selective tromboxane synthetase inhibitor with platelet antiaggregatory and antithrombotic activity. Thromb Res 1981; 23: 145–62
- Jelnes R, Astrup A, Bülow J. The double isotope technique for in vivo determination of the tissue-to-blood partition coefficient for xenon in human subcutaneous tissue—an evaluation. Scand J Clin Lab Invest 1985; 45: 565–8